JPRN-UMIN000006809
Completed
Phase 2
Phase II Study of Paclitaxel and Carboplatin plus Bevacizumab in StageIIIA-N2, IIIB, IV patients with Nonsquamous Non-Small-Cell Lung Cancer - Phase II Study of PTX and CBDCA plus Bevacizumab for Nonsquamous NSCLC
Akita University Graduate School of Medicine0 sites31 target enrollmentDecember 1, 2011
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- chemotherapy-na&
- Sponsor
- Akita University Graduate School of Medicine
- Enrollment
- 31
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Radiation therapy(expect chest) 2\)Patients with untreated Brain metastases 3\)Patients with current or previous history of hemoptysis (2\.5mL or more) 4\)Patients with uncontrolled hypertension 5\)Patients with uncontrolled infection 6\)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, pulmonary fibrosis or drug\-induced pneumonitis 7\)Patients with uncontrollable complications 8\)Patients with massive pleural or pericardial effusion,or ascites 9\)Patients with active concomitant malignancy 10\)Patients with previous histories of drug allergy 11\)Patients with uncontrollable gastrointestinal ulceration 12\)Patients with current or previous (within one year) history of gastrointestinal perforation 13\)Patients with therapeutic anticoagulopathy (including Aspirin over 325mg/day) 14\)Pregnancy or lactation 15\)Inappropriate patients for this study judged by the physicians
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
A Phase II study of Paclitaxel plus Carboplatin plus Bevacizumab that introduces concept of Clinical PD in recurrent or advanced non-squamous non-small cell lung cancer.recurrent or advanced non-squamous non-small-cell and lung cancer.JPRN-UMIN000005328Dept. of Respiratory Medicine, Osaka University Hospital45
Active, not recruiting
Phase 1
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast CancerPreviously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)MedDRA version: 20.0Level: PTClassification code 10006198Term: Breast cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-004651-23-FRInstitut Jules Bordet180
Recruiting
Phase 1
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast CancerPreviously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10075566Term: Triple negative breast cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10006198Term: Breast cancer recurrent Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2024-511850-34-00Institut Jules Bordet209
Active, not recruiting
Phase 1/2
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer2024-511850-34-00Institut Jules Bordet209
Active, not recruiting
Not Applicable
A phase II trial of carboplatin and paclitaxel compared with carboplatin or gemcitabine paclitaxel induction followed by carboplatin/paclitaxel/gemcitabine in patients with suboptimally resected stage III or IV ovarian carcinoma - NDEUCTR2006-000126-31-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI